Randomised, Double-blind, Placebo-controlled Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Multiple Rising Oral Doses of BI 685509 Over 28 Days in Male and Female Patients With Diabetic Nephropathy
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2018
At a glance
- Drugs BI 685509 (Primary)
- Indications Diabetic nephropathies
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 05 Feb 2018 Planned End Date changed from 13 Aug 2018 to 30 Apr 2019.
- 05 Feb 2018 Planned primary completion date changed from 13 Aug 2018 to 30 Apr 2019.
- 19 Oct 2017 Status changed from not yet recruiting to recruiting.